Transcription Factor AP2ε: A potential predictor of chemoresistance in patients with gastric cancer
J Sun, N Du, J Li, J Zhou, G Tao… - Technology in Cancer …, 2016 - journals.sagepub.com
Chemotherapy is a mainstay of therapy for advanced gastric cancer (GC); however, owing to
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …
Transcription Factor AP2ε
J Sun, N Du, J Li, J Zhou, G Tao, S Sun… - Technology in Cancer …, 2015 - cir.nii.ac.jp
抄録< jats: p> Chemotherapy is a mainstay of therapy for advanced gastric cancer (GC);
however, owing to drug resistances, the effectiveness of chemotherapy is not satisfactory for …
however, owing to drug resistances, the effectiveness of chemotherapy is not satisfactory for …
Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer
J Sun, N Du, J Li, J Zhou, G Tao… - Technology in cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Chemotherapy is a mainstay of therapy for advanced gastric cancer (GC); however, owing to
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …
Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.
J Sun, N Du, J Li, J Zhou, G Tao, S Sun… - Technology in Cancer …, 2015 - europepmc.org
Chemotherapy is a mainstay of therapy for advanced gastric cancer (GC); however, owing to
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …
drug resistances, the effectiveness of chemotherapy is not satisfactory for some patients with …